The Inflation Reduction Act (IRA), one of the key legislative achievements the Biden-Harris administration, aims to expand benefits and reduce costs for Medicare beneficiaries. Among its provisions, the IRA introduced…
Certara’s Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this WIRED article about the FDA’s recent rejection of Lykos Therapeutics’ proposed MDMA treatment for post-traumatic…
When it comes to efficient clinical study build, content is king. Most importantly: metadata content. Metadata is the building blocks of your study. It’s the forms, terminologies and datasets you…
aCRFs are a mandatory requirement of the FDA, and therefore a key submission deliverable for any clinical trial. Creating quality annotated case report forms (aCRFs) takes time and attention to…
Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic steatohepatitis (NASH) is one type of NAFLD. Individuals with obesity and type 2 diabetes appear…
系列文章第 2 部分即将发布，敬请关注：FDA/EMA 合规联合建议 — 应对欧盟法规动态立即注册。
The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies to maximize the efficacy of a drug as well as the safety and tolerability. Quantitative…
生命科学行业的许多公司在采用新技术方面进展缓慢。This is often down to budget restrictions, greater operational burden, and uncertainty with meeting complex regulatory requirements. …
RADNOR, PA – 2024 年 8 月 15 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical…
© 2025 Certara. 保留所有权力。 | 隐私政策
